Midland Pharmaceuticals
- | Biotech or pharma, therapeutic R&D
Midland is a clinical stage company formed by NLC Ventures and AstraZeneca to develop MLP-1236 (AZD1236) for the treatment of spinal cord injury and ischemic stroke. MLP-1236 has already completed Phase 1 and Phase 2a clinical trial and was shown to be safe and well tolerated. Midland is seeking to raise a $28M series A financing to advance MLP-1236 through the completion of Phase 2b clinical proof of principle trials in both spinal cord injury and stroke.
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)